158 results
Page 5 of 8
8-K
EX-99.1
edp50zklc8f96935
24 Oct 12
Bristol-Myers Squibb Reports Third Quarter 2012 Financial Results
12:00am
SC TO-T/A
EX-99
clumkbutb9 580l2fus
19 Jan 12
Third party tender offer statement (amended)
12:00am
SC TO-T
EX-99
l012sz
13 Jan 12
Third party tender offer statement
12:00am
SC TO-T
EX-99
95l75qve5 9f
13 Jan 12
Third party tender offer statement
12:00am
8-K
EX-99.1
2dswh9dsn
9 Jan 12
Bristol-Myers Squibb to Acquire Inhibitex
12:00am
8-K
EX-99.1
9rahv7gb6
27 Oct 11
Bristol-Myers Squibb Delivers Strong Third Quarter with Important Clinical Data, Solid Operating Results and Continued Focus on Business Development
12:00am
8-K
EX-99.1
yuyninb
28 Jul 11
Important Clinical Data and Strong Financial Results
12:00am
8-K
EX-99.1
bjphk
27 Jan 11
Receives U.S. Regulatory Approval for KOMBIGLYZE™ XR, and First-Line Indication for SPRYCEL® in Fourth Quarter
12:00am
8-K
EX-99.1
k5q6586
26 Oct 10
Robust Clinical Data and the Strategic Acquisition of ZymoGenetics
12:00am
SC TO-T/A
EX-99
xiaxk3 yw
29 Sep 10
Third party tender offer statement (amended)
12:00am
SC TO-T/A
EX-99
ha8g2j7yst4ws 2k4l
13 Sep 10
Third party tender offer statement (amended)
12:00am
8-K
EX-99.1
m6yrc8
22 Jul 10
Bristol-Myers Squibb Second Quarter Featured Robust Clinical Data
12:00am